Regencell Bioscience Holdings Limited (NASDAQ:RGC) Short Interest Down 28.1% in January

Regencell Bioscience Holdings Limited (NASDAQ:RGC) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 924,708 shares, a decrease of 28.1% from the December 31st total of 1,285,978 shares. Based on an average trading volume of 1,378,413 shares, the short-interest ratio is currently 0.7 days. Approximately 0.2% of the shares of the stock are sold short. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 1,378,413 shares, the short-interest ratio is currently 0.7 days.

Regencell Bioscience Stock Down 10.4%

NASDAQ RGC opened at $24.99 on Friday. The business has a 50 day moving average price of $23.55 and a 200 day moving average price of $17.73. Regencell Bioscience has a 1-year low of $0.09 and a 1-year high of $83.60.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after acquiring an additional 384,250 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Regencell Bioscience during the second quarter worth about $1,701,000. BNP Paribas Financial Markets purchased a new stake in shares of Regencell Bioscience in the second quarter valued at about $768,000. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience in the third quarter valued at about $598,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Regencell Bioscience in the second quarter valued at approximately $222,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.